Dominik Paul Modest
@ModestDominik
Followers
167
Following
9
Media
1
Statuses
39
Health-related quality of life in patients with KRASG12C-mutated chemo...
0
1
2
🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. @JenSeligmann & Dr @ModestDominik share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI
0
8
27
🚨#LowerGIcancer highlights from #ASCO24🚨 Medical oncologists Prof. @JenSeligmann and Dr @ModestDominik share their views on new data in #rectalcancer and #CRC from the NEOPRISM-CRC trial & LBA3512. Watch the video 📺 👇 #MedEd #oncology #CRCSM
1
13
41
Voting open for @myESMO #president 2027-2028! Vote now, or on your way to #ASCO24! My vote 👇 @Prof_Nadia_H #mentor #strong #womenleaders #femalepresident
0
16
31
Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) https://t.co/mLuAayTmTM
#ESMO23 #oncology
1
36
106
Five @giconnectInfo experts provide a handy update from #ESMO2022! ➡️ Podcast Ep. 1: Lower #GIcancer highlights ➡️ Podcast Ep. 2: Upper #GIcancer highlights ➡️ Video summary of NICHE-2 trial For the podcasts, video and downloadable content, follow: https://t.co/NOldiEyHaB
#MedEd
cor2ed.com
Podcast episode 1: lower GI cancer Dr Jenny Seligmann and Dr Dominik Modest discuss key abstracts on lower GI cancer from ESMO 2022 in Episode 1 of this
0
3
7
💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer 💥short duration safe pre-op 💥4% grade 3 events 💥100% R0 resection 💥95% major path; 67% pCR …round of applause in session! 1/2
5
51
146
Niche-2. No need for further interpretation… congrats to Myriam!! What a perfect presentation of a super trial. Great that we had a wowww moment in colon cancer.
0
6
23
Great to see randomized data. Congratulations!! Great achievement. Final conclusion (do it or not) more complex. Data suggest that HIPEC influences local but not systemic control and systemic relapse is a frequent issue.
HIPECT4 shows that HIPEC with MMC in effective and safe to prevent peritoneal relapse in T4 colorectal cancer, presented in @myESMO 2022. @AndreaCercek @PSOGI_EC @ESSOnews @aecirujanos @_SEOM @indepso @ISSPP1 @HUReinaSofia @IMIBIC @SeguraJuanJ @operarelcancer @GECOP_ @PSugarbaker
1
4
11
Late check-out and ready to fly back home🇮🇹! This has been an incredible ASCO for science, meeting new and old friends, discussing projects and also..so much laughing ! @ChiaraCrem1 @lonardi_sara @MyriamChalabi @BenWestphalen @JenSeligmann @ModestDominik @darioT_ @PTarantinoMD
0
1
2
Proud to present our subgroup analysis of the PANAMA-study according to #gender and age in patients with #colorectalcancer at #ASCO2022! Thanks to my amazing mentors @ModestDominik and @StintzingS for their support!
0
6
21
The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer. https://t.co/RQySqOYS7u
@ModestDominik
@Sauer_et_al
link.springer.com
BMC Cancer - Additive/adjuvant chemotherapy as concept after local treatment of colorectal metastases has not been proven to be successful by phase III trials. Accordingly, a standard of care to...
1
5
8
Our new podcast series is out! In Episode 2 @JenSeligmann, @McreeAutumn and @ModestDominik are discussing #immunotherapy approaches! Listen to the podcast and download the transcript at: https://t.co/jkF0NKqdMJ
#MedEd #GI #GC
0
1
1
Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum
charite.de
Pressemitteilungen der Charité – Universitätsmedizin Berlin
1
6
13
Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC. #ASCO21 | @ModestDominik
https://t.co/e1iPG3xlkR
0
1
0
@manjuggm @OncoAlert You guessed it... having an opinion is not knowing it. 😉
1
2
4